Kali Therapeutics, Inc.
Clinical trials sponsored by Kali Therapeutics, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New RA drug enters first human safety trial Results expected Feb 2027 (estimated)
-
New antibody drug takes aim at rheumatoid arthritis in first human trial
Disease control Recruiting nowThis early-stage trial tests a new drug called KT502 in 27 adults with moderate to severe rheumatoid arthritis. The drug is designed to deplete certain immune cells (B cells) that contribute to joint inflammation. The main goal is to check safety and find the right dose, not yet …
Phase 1 • Sponsor: Kali Therapeutics, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New RA drug enters first human safety trial
Disease control Recruiting nowThis early-stage study tests a new drug, KT501, in 24 adults with moderate to severe rheumatoid arthritis (RA). The main goal is to check safety and how the body handles the drug after a single injection. Participants must have had RA for at least 6 months and not responded well …
Phase 1 • Sponsor: Kali Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC